CHRAC1

Across TCGA pan-cancer cohorts, CHRAC1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHRAC1 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CHRAC1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CHRAC1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where CHRAC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.985	0.067	.008	22	view →
LSCC	DFS	Median	II,III,IV	0.859	0.514	.003	19	view →
PDAC	DFS	Tertile	III,IV	0.498	0.979	.006	12	view →
COAD	DFS	Median	III,IV	0.856	1.000	.046	6	view →
OV	DFS	Median	All	0.854	1.000	.025	4	view →
LUAD	OS	Quartile	III,IV	1.000	0.378	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHRAC1–CCRCC (DFS)

Open the CCRCC breakdown →